- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01334827
A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users (Project-MIST)
December 7, 2020 updated by: The Miriam Hospital
Rational Development of Combination Microbicide Therapies: A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users (Project MIST)
The purpose of the study is to compare, contrast, and characterize the range of user perceptions and potential acceptability of three (3) topical vaginal microbicide dosage forms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The success of microbicide products will derive from the synergy of their biological functionality and user acceptability.
Biological functionality is the integrated result of safe and effective anti-HIV compounds incorporated into dosage forms or devices that successfully deliver those compounds to target tissues, fluids, and pathogens.
Acceptability is a multi-factorial phenomenon that accounts for the personal, dyadic, product-related, and social contexts that potentiate - or not - a woman's decision to use a microbicide.
Acceptability (assessed, in part, by the users' sensory perceptions of products during use) depends strongly upon dosage forms and/or delivery systems with biophysical functions and/or mechanical and materials properties that are most conducive to human use.
Without both, microbicides' potential to decisively alter the public health impact of HIV/AIDS and other sexually transmitted infections will be largely limited.
The current protocol will specifically study the impact of gel volume on user perceptions, as well as extend user perception scale development to include those properties and product "behaviors" experienced when using a vaginal film.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Miriam Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Women who:
- are between the ages of 18 and 45
- report vaginal sex with their male sexual partner in the past 6 months
- report being in a monogamous sexual relationship with their male partner
- report consistent use of an effective birth control method: e.g., hormonal contraceptive, IUD, bilateral tubal ligation, Essure® or any non-incisional permanent birth control procedure, hysterectomy (partial or total, with/without oophorectomy), partner's vasectomy/salpingectomy
- are able to tolerate film use, as measured by pelvic exam at Visit 1B
- are willing to refrain from any vaginal product use (inclusive of douching) for 48 hours before Visit 1B and until they complete all study activities (except for study-related products)
- are willing to refrain from having vaginal intercourse 24 hours before Visit 1B and Visits 2-4
- are willing to use condoms for vaginal-penile sex between all study visits (Visits 1A - 4)
- are willing to refrain from any non-penile vaginal penetration during dosage form evaluation visits (Visits 2-4)
- are willing to undergo HIV testing and receive test results and counseling.
Men who:
- are at least 18 years of age
- report vaginal sex with their female sexual partner in the past 6 months
- report being in a monogamous sexual relationship with their female sexual partner
- are willing to refrain from having vaginal intercourse 24 hours before Visit 1B and Visits 2-4
- are willing to use condoms for vaginal-penile sex between all of study visits (Visits 1A-4)
- are willing to refrain from any non-penile vaginal penetration during dosage form evaluation visits (Visits 2-4)
- are willing to use a non-lubricated latex condom (provided) for penile-vaginal intercourse during dosage form evaluation visits (Visits 2-4)
- are willing to undergo HIV testing and receive test results and counseling.
Exclusion Criteria:
Women and men will be ineligible if:
- they are unable or unwilling to give informed consent
- their partner is unable or unwilling to give informed consent
- they are currently enrolled in other vaginal product study/studies
- they are STI (Neisseria gonorrhea, Chlamydia trachomatis, bacterial vaginosis, trichomoniasis, syphilis), HIV positive upon screening (Visit 1A), or pregnant (females) at any study visit
- they are breastfeeding, or have completed menopause (i.e., at least 12 months without menstrual periods) (female participants only)
- they are currently attempting to get pregnant or have an intention to get pregnant during their participation in the study
- they have clinically significant abnormal pelvic findings and/or findings requiring therapy as a function of clinical exam at Visits 1A and/or 1B (female participants only)
- they report being within 30 days of their last pregnancy outcome or gynecologic surgical procedure
- they have known, or suspected, allergies to any component of the study products or similar ingredients in other products
- they have known, or suspected, allergies to latex
- they have any condition that, in the opinion of the study clinician or principle investigator, would compromise the participant´s ability to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Formulations
high volume gel; low volume gel; vaginal film
|
4 mL HEC
Other Names:
2 mL HEC
Other Names:
1" x 2" intravaginal quick-dissolving film
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
User Sensory Perception & Experience (USPE; Perceptibility) Scale Item Means
Time Frame: 4-5 visits over an average of 8-12 weeks
|
USPE Sum of averaged item means/# items (min:max 1:5); 1=Do not agree at all;2=Agree a little;3=Agree somewhat;4=Agree a lot;5=Agree completely.
Products:Low volume gel, high volume gel, film.Initial Penetration:Smoothness/lubricity; Initial Lubrication:Coating/lubricating; Spreading Behavior:Ease of stroke, product spread; Product Awareness:Feel intravaginally during sex (movement, felt betw vaginal wall-penis); Perceived Wetness:Covering entire vagina; as after orgasm; Stimulating: enhanced pleasure; Messiness:Perceptions of watery/messiness; Leakage:Sensations of leaking during/after sex; in pubic hair; need to clean; Pre-coital Leakage:Product felt/leakage noticed on panty liner before sex; Naturalness:Sensation of naturalness; leakage looked like vaginal fluid; Lubricity:Wetness before sex; slipperiness/lubricity during sex; Effortful:Effort needed at penetration; effort difficulty/dryness; Pleasure:Partner's stimulation; Noticeable:Male sensation during sex, messiness, thickness
|
4-5 visits over an average of 8-12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Buckheit, PhD, ImQuest Pharmaceuticals
- Principal Investigator: Kathleen Morrow, PhD, The Miriam Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
April 11, 2011
First Submitted That Met QC Criteria
April 12, 2011
First Posted (Estimate)
April 13, 2011
Study Record Updates
Last Update Posted (Actual)
December 8, 2020
Last Update Submitted That Met QC Criteria
December 7, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 11800
- R33AI076967 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbicide Delivery System Acceptability
-
The Miriam HospitalNational Institute of Allergy and Infectious Diseases (NIAID); ImQuest Pharmaceuticals...CompletedMicrobicide Delivery System Perceptibility and AcceptabilityUnited States
-
The Miriam HospitalNational Institute of Allergy and Infectious Diseases (NIAID); ImQuest Pharmaceuticals...CompletedMicrobicide Delivery System Perceptibility and AcceptabilityUnited States
-
Glyciome, LLCBrigham and Women's Hospital; University of Puerto RicoCompletedSensory Perceptual Characteristics | User Acceptability of Gel Delivery SystemUnited States, Puerto Rico
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Society of Family Planning; Rakai Health Sciences...CompletedAcceptability of Different Contraceptive Injection TypesUganda
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)RecruitingElectronic Nicotine Delivery System FlavorsUnited States
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
Postgraduate Institute of Medical Education and...CompletedAnesthesia | Closed Loop Anesthesia Delivery System (CLADS)India
-
Tel-Aviv Sourasky Medical CenterUnknownChronic Pain | Pre - Delivery Pregnant Women | Pain During DeliveryIsrael
-
Columbia UniversityNational Center for Advancing Translational Sciences (NCATS)CompletedStroke | Hypertension | Health Care AcceptabilityUnited States
-
University of MichiganCompletedAcceptability of Health Care | HIV Primary InfectionUnited States
Clinical Trials on high volume gel
-
Zhejiang UniversityCompletedOptimal Intensity of Renal Replacement Therapy on Sepsis PatientsChina
-
AHS Cancer Control AlbertaCompleted
-
Peking University Third HospitalRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Amsterdam UMC, location VUmc; Leiden University Medical Center; Gelre Hospitals; Tergooi Hospital and other collaboratorsCompleted
-
Inje UniversityCompletedColonoscopy | Bowel PreparationKorea, Republic of
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS); TIRR Memorial... and other collaboratorsRecruitingSpinal Cord InjuriesUnited States
-
Universitätsklinikum Hamburg-EppendorfUnknownPulmonary Ventilation; Newborn, AbnormalGermany
-
University of Alabama at BirminghamCentre for Infectious Disease Research in Zambia; Chiesi FoundationCompletedPostnatal Growth RestrictionZambia
-
Virginia Commonwealth UniversityRecruitingPeripheral Vascular DiseasesUnited States
-
Federal University of Rio Grande do SulCompleted